Activated protein C (APC)-resistance prevalence or FVL carrier frequency range from around 12 to 20 percent in patients who are primarily Caucasian and have experienced a first-ever venous thromboembolism, and they are linked to an increased risk of venous thromboembolism by 2.7 to 6.6 times [9,10,11]. Here, APC is linked to venous thromboembolism.